Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the ...

April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed ...

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.

Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.73 per share, reflecting a decline of 3.5% compared to the same period last year. Revenues ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

Shares of Merck and Amgen are seeing declines Friday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow Dow Jones Industrial Average was most rece ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's ...